Pancragen

Pancragen is Lys-Glu-Asp-Trp with an amidated C-terminus — KEDW-NH2 — indexed by the US National Library of Medicine as lysyl-glutamyl-aspartyl-tryptophanamide with a note of homeostatic and endothelioprotective activity. Among the organ-branded bioregulators it is the one whose file contains something a diabetologist would recognise as an experiment: a metabolic endpoint, in a primate, against an active comparator drug.

The mechanistic claim is the family claim — a short peptide entering the nucleus and altering transcription — but here it was pursued in pancreatic tissue. Ageing pancreatic cell cultures showed shifts in differentiation markers ( Bull Exp Biol Med 2013), and molecular-mechanics modelling argued for a preferred DNA binding geometry ( Bull Exp Biol Med 2014). Modelling predicts binding; it does not show that binding drives insulin secretion.

Pancragen holds no licence for diabetes, pancreatitis or exocrine insufficiency. In rats with experimentally induced diabetes it was reported to lower blood glucose and alter capillary permeability and adhesion ( Bull Exp Biol Med 2007). The realistic alternatives — metformin, GLP-1 receptor agonists, insulin — all carry cardiovascular outcome trials.

Category S0 captures pharmacological substances lacking approval by any government health authority for human therapeutic use, which describes this peptide. Not being listed by name protects nobody; get a written answer from the relevant anti-doping organisation.

No human tolerability study has been published, and five treated animals over ten days cannot characterise safety. The hazard worth naming is hypoglycaemia: anything marketed as lowering blood sugar becomes dangerous alongside prescribed glucose-lowering medication, and no interaction data exist for this peptide.

The one citable dose comes from the monkey experiment: 0.05 mg per animal per day, intramuscularly, for ten days. That is an animal protocol from a Russian gerontology journal, reproduced here only so readers can see what the evidence looked like. Human pharmacokinetics have never been measured.

It ships as a lyophilised powder, sometimes cross-listed with "metabolic stacks". No published study has combined KEDW with any other agent, so those pairings are invented at the point of sale.

Nine aged female rhesus monkeys of 20–25 years were split into five receiving Pancragen and four receiving glimepiride 4 mg orally. Both lowered baseline glucose; the authors reported that Pancragen normalised insulin and C-peptide, while glimepiride produced a stronger but delayed hypoglycaemic effect ( Goncharova et al., Adv Gerontol 2015, in Russian; see also the companion report in Adv Gerontol 2014). Read plainly: an unblinded five-versus-four comparison, published in Russian by the developers, never replicated — and the high-water mark for this entire class of compound.

For deeper dives on this peptide, see:

• Pancragen benefits and areas of interest
• Pancragen side effects and safety context
• Pancragen dosing concepts (educational)
• Pancragen research and evidence overview

Is there human evidence for Pancragen? A 2011 paper discusses prospects in elderly people ( Bull Exp Biol Med 2011), but no randomised controlled trial has been published or registered. The substantive in-vivo data are the rat and rhesus experiments.

How does it differ from Prostamax and Livagen? All three share the Lys-Glu-Asp opening; Pancragen ends in tryptophan and is amidated, Prostamax in proline, Livagen in alanine. Only Pancragen has been tested against a licensed comparator drug.

Could it replace a diabetes medication? Nothing published supports substituting it for a treatment with outcome data, and stacking an unstudied glucose-lowering claim onto prescribed therapy is where hypoglycaemia risk arises.

Is it approved anywhere? No FDA, EMA or MHRA authorisation exists. Its National Library of Medicine record is an index entry for a chemical named in papers, not a regulatory status.